For weight management, NICE has approved semaglutide (Wegovy) for adults with specific BMI criteria (35 kg/m or 30 kg/m with weight-related comorbidities) within specialist weight management services
Direct comparisons with semaglutide or tirzepatide should be interpreted with caution, as no head-to-head trials have been conducted
Cysteamine treatment causes intralysosomal formation of a cysteaminecysteine mixed disulfide, capable of exiting the lysosome purportedly via the lysine excretion pathway
Of the patients who were switched, 11.1% experienced a gastrointestinal (GI) adverse effect (AE)
If additional glycemic control is needed, the dose may be increased to 1 mg weekly after at least four weeks, and potentially to 2 mg weekly after another four weeks at 1 mg
These insights can support a more informed conversation between patient and provider about whether tirzepatide's dual-axis mechanism or semaglutide's GLP-1-only approach aligns better with each person's genetic and metabolic profile
